Headache in Primary Care *
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Acupressure for Tension Headache
MANUAL THERAPY Malissa Martin, EdD, ATC, CSCS, Report Editor Acupressure for Tension Headache Sandra Hendrich, PT, DPT; Leamor Kahanov, EdD, LAT, ATC; and Lindsey E. Eberman, PhD, LAT, ATC • Indiana State University Tension headache (TH) or “stress head- milder severity and longer duration and is ache” is the most common type of headache generally described as a feeling of tightness occurring among adults, occurring twice as or a band-like pressure felt around the back often in women as in men, and a leading of the neck or the head or in the forehead health complaint.1,2,3 Exercise-related head- region.1-4 The pain associated with TH is usu- aches are one of the ally dull in nature and generally occurs on most common medical both sides of the head. Tight muscles in the Key PPointsoints problems affecting ath- neck, shoulders, upper back, and temporal Addressing three key acupressure points letes, with up to 50% regions, often accompanied by stress, may (temporal, base of the skull, first dorsal reporting headache as be an indication that myofacial trigger points 1-4 interossi) may reduce or eliminate tension a regular consequence (MTPs) are a cause of TH. headache symptoms. of athletic participa- Treatment may include psychological tion.4 A majority (72%) counseling, manual therapy, physiologic Accupressure points (i.e., Joining of the of these athletes report intervention, and pharmaceutical treat- Valleys, LI4; Gates of Consciousness, that neither trauma or ment.1,3 An association between MTPs and GB20; and the temporal region) may be concussion is the cause, TH has been identified, with treatment ame- specific to tension headaches but may also and therefore, such liorating or eliminating symptoms.2,3 MTPs be hypersensitive muscles delineated by a headaches can be cat- in the upper trapezius, sternocleidomastoid taut band of tissues. -
Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine -
Migraine; Cluster Headache; Tension Headache Order Set Requirements: Allergies Risk Assessment / Scoring Tools / Screening: See Clinical Decision Support Section
Provincial Clinical Knowledge Topic Primary Headaches, Adult – Emergency V 1.0 © 2017, Alberta Health Services. This work is licensed under the Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use. Revision History Version Date of Revision Description of Revision Revised By 1.0 March 2017 Topic completed and disseminated See Acknowledgements Primary Headaches, Adult – Emergency V 1.0 Page 1 of 16 Important Information Before You Begin The recommendations contained in this knowledge topic have been provincially adjudicated and are based on best practice and available evidence. Clinicians applying these recommendations should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care. This knowledge topic will be reviewed periodically and updated as best practice evidence and practice change. The information in this topic strives to adhere to Institute for Safe Medication Practices (ISMP) safety standards and align with Quality and Safety initiatives and accreditation requirements such as the Required Organizational Practices. -
The In¯Uence of Medication on Erectile Function
International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted. -
Deprescribing Anticholinergic and Sedative Medicines: Protocol for a Feasibility Trial (DEFEAT- Polypharmacy) in Residential Aged Care Facilities
Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2016-013800 on 16 April 2017. Downloaded from Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT- polypharmacy) in residential aged care facilities Nagham Ailabouni,1 Dee Mangin,2 Prasad S Nishtala1 To cite: Ailabouni N, ABSTRACT Strengths and limitations of this study Mangin D, Nishtala PS. Introduction: Targeted deprescribing of Deprescribing anticholinergic anticholinergic and sedative medicines can lead to ▪ and sedative medicines: Using a quantitative measure (ie, the Drug Burden positive health outcomes in older people; as they have protocol for a Feasibility Trial Index) will help to determine the effect of depre- (DEFEAT-polypharmacy) in been associated with cognitive and physical scribing anticholinergic and sedative medicines. residential aged care facilities. functioning decline. This study will examine whether ▪ A pharmacist conducting in-depth medicine BMJ Open 2017;7:e013800. the proposed intervention is feasible at reducing the reviews could help to alleviate time constraints doi:10.1136/bmjopen-2016- prescription of anticholinergic and sedative medicines often faced by general practitioners in the resi- 013800 in older people. dential care setting. Methods and analysis: The Standard Protocol ▪ Six months may not be adequate to fully investi- ▸ Prepublication history and Items: Recommendations for Interventional trials gate the clinical effects of deprescribing. additional material is (SPIRIT checklist) was used to develop and report the available. To view please visit protocol. Single group (precomparison and the journal (http://dx.doi.org/ postcomparison) feasibility study design. 10.1136/bmjopen-2016- Study population: 3 residential care homes have INTRODUCTION 013800). been recruited. -
Headache: a Patient's Guide (Pdf)
Headache A Patient’s Guide Kathleen Digre, MD • Susan Baggaley, APRN • K.C. Brennan, MD • Seniha Ozudogru, MD 729 Arapeen Drive Salt Lake City, Utah 84108 801.585.7575 headache.uofuhealth.org Headache: A Patient’s Guide eadache is an extremely common problem. It is estimated that 10-20% of all people have migraine. Headache is one of the most common reasons H people visit the doctor’s office. Headache can be the symptom of a serious problem, or it can be recurrent, annoying and disabling, without any underlying structural cause. WHAT CAUSES HEAD PAIN? Pain in the head is carried by certain nerves that supply the head and neck. The trigeminal system impacts the face as well as the cervical (neck) 1 and 2 nerves in the back of the head. Although pain can indicate that something is pushing on the brain or nerves, most of the time nothing is pushing on anything. We think that in migraine there may be a generator of headache in the brain which can be triggered by many things. Some people’s generators are more sensitive to stimuli such as light, noise, odor, and stress than others, causing a person to have more frequent headaches. THERE ARE MANY TYPES OF HEADACHES! Most people have more than one type of headache. The most common type of headache seen in a doctor's office is migraine (the most common type of headache in the general population is tension headache). Some people do not believe that migraine and tension headaches are different headaches, but rather two ends of a headache continuum. -
Preventive Report Appendix
Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents. -
A Characteristic Ganglioside Antibody Pattern in the CSF of Patients With
Journal ofNeurology, Neurosurgery, and Psychiatry 1993;56:361-364 361 A characteristic ganglioside antibody pattern in J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.56.4.361 on 1 April 1993. Downloaded from the CSF of patients with amyotrophic lateral sclerosis Andreas Stevens, Michael Weller, Horst Wietholter Abstract Materials and methods Paired cerebrospinal fluid and serum Thirty five patients with amyotrophic lateral samples of patients with amyotrophic sclerosis, 16 men and 19 women, mean age lateral sclerosis (n = 35) revealed no con- 53-5 (2 4) years, range 25-79 years at diag- sistent abnormalities of CSF cell count, nosis, without a family history of the illness, CSF albumin, CSF IgG, CSF IgM, IgG were included in this study. The diagnosis or IgM index, or oligoclonal immuno- was clinical and based on the presence of globulin band formation in the CSF. both upper and lower motor neuron symp- Determination of IgG and IgM CSF and toms and signs. Eight patients had prominent serum antibodies to gangliosides GM1, bulbar signs, 31 had definite spasticity. For GM2, GM3, AGMI, GDla, GDlb, and inclusion in this study, the onset of symptoms GTlb showed a characteristic pattern had to be insidious and not started before the which allowed the differentiation of age of 20. The clinical course had to be amyotrophic lateral sclerosis from con- progressive. Specific attention was given to trols and from patients with other neuro- alternative diagnoses of cervical spondylosis, logical disorders including multiple neoplastic lesions of cervical spinal cord sclerosis. Specifically, patients with the and brain stem, polymyositis, peripheral disease had elevated CSF IgM antibodies neuropathy, progressive muscle atrophy, to all gangliosides except AGMI. -
Tension-Type Headache CQ III-1
III Tension-type headache CQ III-1 How is tension-type headache classified? Recommendation Since 1962, various classifications for tension-type headache have been proposed. Currently, classification according to the International Classification of Headache Disorders 3rd Edition (beta version) (ICHD-3beta) published in 2013 is recommended. Grade A Background and Objective Diagnostic classification that forms the basis of guidelines is certainly important for formulating clinical care and treatment policies. The ICHD-3beta is not simply a document based on classification, it also addresses diagnosis and treatment scientifically and practically from all aspects. Comments and Evidence The classification of tension-type headache (TTH) is provided by the International Classification of Headache Disorders 3rd edition beta version (ICHD-3beta).1)2) The division of tension-type headache into episodic and chronic types adopted by the first edition of the International Classification of Headache Disorders (1988)3) is extremely useful. The International Classification of Headache Disorders 2nd edition (ICHD-II) further subdivides the episodic type according to frequency, and states that this is based on the difference in pathophysiology. The former episodic tension-type headache (ETTH) is further classified into 2.1 infrequent episodic tension-type headache (IETTH) with headache episodes less than once per month (<12 days/year), and 2.2 frequent episodic tension-type headache (FETTH) with higher frequency and longer duration (<15 days/month). The infrequent subtype has little impact on the individual, and to a certain extent, is understood to be within the range of physiological response to stress in daily life. However, frequent episodes may cause disability that sometimes requires expensive drugs and prophylactic medication. -
Biochemistry of Blood and Cerebrospinal Fluid in Tension-Type Headaches
P1: KWW/KKL P2: KWW/HCN QC: KWW/FLX T1: KWW GRBT050-75 Olesen- 2057G GRBT050-Olesen-v6.cls August 5, 2005 20:30 ••Chapter 75 ◗ Biochemistry of Blood and Cerebrospinal Fluid in Tension-Type Headaches Flemming W. Bach and Michel D. Ferrari The literature on biochemistry in tension-type headache tors, were reported to be reduced in patients with TTH (TTH) is characterized by the pursuit of a large variety of in headache-free periods and further lowered during ideas about pathophysiology, and it may therefore appear headache in analogy with what was seen in migraine (59). somewhat dispersed and confusing. Indeed, in many cases Schoenen et al., on the other hand, found similar magne- similar studies have been performed that yielded contra- sium concentrations in chronic TTH and control subjects dictory results, and there may be many reasons for this. (60). Lactic and pyruvic acid levels are normal in TTH (55). First, many different designations, including chronic daily headache, (chronic) muscle contraction headache, tension headache, and chronic migraine; definitions; and Peptides criteria have been used in the past to describe clinically pa- Several peptides have been studied in TTH, and the en- tients suffering from unspecified headaches. This severely dogenous opioid peptides β-endorphin and methionine- hampers straightforward comparison of the results. Only enkephalin (met-enkephalin) received much attention in recent years have most investigators used the 1988 crite- for a period. The idea was that headache was a ria (38). Second, exclusion criteria also vary markedly, the hypoendorphin-syndrome (66). It appears from Table 75-1 most important being the use of medication at the time of that the data are inconsistent with regard to this idea. -
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines -
Zebrafish Embryo Screen Identifies Anti-Metastasis Drugs
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.04.434001; this version posted March 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Zebrafish embryo screen identifies anti-metastasis drugs 2 3 Joji Nakayama1,2,3,4§, Lora Tan1, Boon Cher Goh2, Shu Wang1, 5, Hideki Makinoshima3,6 and 4 Zhiyuan Gong1§ 5 6 1Department of Biological Science, National University of Singapore, Singapore 7 2Cancer Science Institute of Singapore, National University of Singapore, Singapore 8 3Tsuruoka Metabolomics Laboratory, National Cancer Center, Tsuruoka, Japan 9 4Shonai Regional Industry Promotion Center, Tsuruoka, Japan. 10 5Institute of Bioengineering and Nanotechnology, Singapore 11 6Division of Translational Research, Exploratory Oncology Research and Clinical Trial 12 Center, National Cancer Center, Kashiwa, Japan. 13 14 Keywords: Zebrafish, metastasis, gastrulation, phenotyping screening 15 16 §Corresponding authors: 17 Joji Nakayama 18 Tsuruoka Metabolomics Laboratory, National Cancer Center, Mizukami 246-2, Kakuganji, 19 Tsuruoka, Yamagata, Japan 975-0052. 20 email: [email protected] 21 22 Zhiyuan Gong 23 Department of Biological Science, National University of Singapore, Singapore 117543. 24 email: [email protected] 25 26 The authors disclose no potential conflicts of interest. 27 Total words excluding abstract, material and methods, references, and figure legends: 1390 28 Number of figures: 2 29 Number of supplementary figures: 3 30 Number of supplementary tables: 3 31 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.04.434001; this version posted March 5, 2021.